Abstract
Mannuronate oligosaccharide (MOS) is α-D-mannuronic acid polymer with 1,4-glycosidic linkages that possesses beneficial biological properties. The aim of this study was to investigate the hypouricemic effect of MOS in hyperuricemic mice and demonstrate the possible protective mechanisms involved. In this research, 200 mg/kg/day of MOS was orally administered to hyperuricemic mice for four weeks. The results showed that the MOS treatment significantly reduced the serum uric acid (SUA) level from 176.4 ± 7.9 μmol/L to 135.7 ± 10.9 μmol/L (p < 0.05). MOS alleviated the inflammatory response in the kidney. Moreover, MOS promoted uric acid excretion by regulating the protein levels of renal GLUT9, URAT1 and intestinal GLUT9, ABCG2. MOS modulated the gut microbiota in hyperuricemic mice and decreased the levels of Tyzzerella. In addition, research using antibiotic-induced pseudo-sterile mice demonstrated that the gut microbiota played a crucial role in reducing elevated serum uric acid of MOS in mice. In conclusion, MOS may be a potential candidate for alleviating HUA symptoms and regulating gut microbiota.
Funder
National Key Research and Development Program of China
Subject
Food Science,Nutrition and Dietetics
Reference76 articles.
1. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China;Song;Sci. Rep.,2018
2. The role of diet in hyperuricemia and gout;Yokose;Curr. Opin. Rheumatol.,2021
3. Butler, F., Alghubayshi, A., and Roman, Y. (2021). The Epidemiology and Genetics of Hyperuricemia and Gout across Major Racial Groups: A Literature Review and Population Genetics Secondary Database Analysis. J. Pers. Med., 11.
4. Geographical distribution of hyperuricemia in mainland China: A comprehensive systematic review and meta-analysis;Huang;Glob. Health Res. Policy,2020
5. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease;Borghi;Eur. J. Intern. Med.,2020
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献